Mounting Debt and Legal Risks Sink Rite Aid Into Distress
Company faces billions of maturities due in coming years
Welcome to The Brink. I’m Diana Li, a reporter in New York, where we’re taking a closer look at the future of pharmacy chain Rite Aid. We also have the latest on Tupperware and Serta Simmons. Follow this link to subscribe. Send us feedback and tips at dli631@bloomberg.net or Tweet/DM to @diana_k16.
It was almost a year ago that Rite Aid turned down a buyout offer from a hedge fund. The price dangled that day for the drugstore chain: $14.60 per share.